StartCRL • NYSE
add
Charles River Laboratories
201,87 $
Efter lukketid:(0,00 %)0,00
201,87 $
Lukket: 16. aug., 17.29.10 GMT-4 · USD · NYSE · Ansvarsfraskrivelse
Seneste lukkekurs
202,09 $
Dagsinterval
200,44 $ - 203,53 $
Årsinterval
161,65 $ - 275,00 $
Markedsværdi
10,42 mia. USD
Gns. volumen
814,28 t
P/E-værdi
24,11
Udbytteprocent
-
Primær børs
NYSE
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 1,03 mia. | -3,19 % |
Driftsudgifter | 197,42 mio. | -14,98 % |
Nettoindtægt | 94,08 mio. | -3,03 % |
Overskudsgrad | 9,17 | 0,22 % |
Earnings per share | 2,80 | 4,09 % |
EBITDA | 256,39 mio. | 3,79 % |
Effektiv afgiftssats | 21,22 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 179,21 mio. | -10,59 % |
Samlede aktiver | 7,95 mia. | 2,26 % |
Samlede passiver | 4,18 mia. | -6,65 % |
Samlet egenkapital | 3,77 mia. | — |
Shares outstanding | 51,63 mio. | — |
Kurs/indre værdi | 2,80 | — |
Afkast af aktiver | 5,29 % | — |
Afkast af kapital | 6,35 % | — |
Pengestrøm
Nettoændring i likviditet
(USD) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 94,08 mio. | -3,03 % |
Pengestrøm fra drift | 193,54 mio. | 30,66 % |
Pengestrøm fra investering | -61,87 mio. | 19,24 % |
Pengestrøm fra finansiering | -285,86 mio. | -300,00 % |
Nettoændring i likviditet | -157,53 mio. | -138.085,09 % |
Fri pengestrøm | 145,77 mio. | 120,91 % |
Om
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
According to the company, it supported the development of approximately 85% of novel FDA-approved drugs in 2021.
Its customers include leading pharmaceutical, biotechnology, agrochemical, government, and academic organization around the globe. The company has over 90 facilities, operates in 20 countries, and employs approximately 18,400 people worldwide.
Charles River Laboratories is often criticized by animal rights activists who condemn the company's usage of dogs and non-human primates for pharmaceutical purposes. The company is also a major harvester of horseshoe crab blood. Wikipedia
Administrerende direktør
Grundlagt
1947
Hovedkvarter
Website
Ansatte
21.100